MedTrace Logo

Primary Aldosteronism in Western Norway

NCT02832388 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-11-08

No results posted yet for this study

Summary

In this study the investigators aim to identify and include consecutively patients with primary aldosteronism (PA) diagnosed in the Western and Mid-parts of Norway, to describe the characteristics of these patients, to explore the cardiac effects of PA before and after specific treatment, and to identify long-term outcomes after treatment. One subgroup of the PA patients perform echocardiography to assess left ventricular systolic myocardial function before and after treatment. One subgroup of PA patients perform cardiac MRI to assess myocardial mass, myocardial fibrosis and myocardial function in rest and during stress, before and after treatment. For the cardiac MRI substudy, the PA patients are compared with a group of healthy controls, also included in the study.

From 2022 onwards, PA patients diagnosed or subtyped with adrenal vein sampling at Oslo University Hospital will additionally be included in the study, thereby providing a national registration of PA patients.

Conditions

  • Hyperaldosteronism

Sponsors & Collaborators

  • Oslo University Hospital

    collaborator OTHER

  • Helse Stavanger HF

    collaborator OTHER_GOV

  • Helse Fonna

    collaborator OTHER

  • University Hospital of North Norway

    collaborator OTHER

  • St. Olavs Hospital

    collaborator OTHER

  • Alesund Hospital

    collaborator OTHER

  • Haukeland University Hospital

    lead OTHER

Principal Investigators

  • Marianne A Grytaas, MD PhD · Haukeland University Hospital

  • Anders P Jørgensen, MD PhD · Oslo University Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02832388 on ClinicalTrials.gov